Citi lowered the firm’s price target on Cooper Companies (COO) to $80 from $87 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The “walls of worry are high” into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm’s top picks are now Edwards Lifesciences and Intuitive Surgical.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COO:
- Cooper Companies Earnings Call Highlights Growth, Higher EPS
- Raising the Bar: Buy Rating on Cooper Driven by Margin Expansion, EPS Growth, and Confidence in Premium Lens Portfolio
- Cooper Companies: Solid Earnings and Fertility Recovery Offset by Sluggish Core Vision Growth, Warranting a Hold Rating
- Cooper Companies price target raised to $101 from $99 at Needham
- Cooper Companies price target lowered to $87 from $88 at Citi